ACTELION, ROCHE REVEAL EXCLUSIVE WORLDWIDE COLLABORATION FOR S1P1 RECEPTOR AGONIST

Actelion revealed that it has entered into exclusive worldwide collaboration with Roche to jointly develop and commercialize its selective S1P1 receptor agonist, an immunomodulator with the potential for once-a-day oral dosing. The company stated that the compound is currently being developed in Phase I. The companies stated that they have planned to jointly develop and commercialize this novel compound for multiple autoimmune disorders. Trading Markets (http://www.tradingmarkets.com/tm.site/news/BREAKING%20NEWS/306548/)